Formulation and evaluation of itraconazole-loaded nanoemulgel for efficient topical delivery to treat fungal infections
Aim: The clinical application of conventional oral dosage form of itraconazole is limited due to its poor bioavailability. The aim of the study was to develop nanoemulgel of Itraconazole for topical delivery. Method: Nanoemulsions were prepared, optimized and further incorporated into a gel and evaluated for homogeneity, pH, viscosity, spreadability, in vitro drug release and skin irritation studies. Results: Cumulative drug release from nanoemulsions was within the range of 37.24 to 47.63% at 10 h. Drug release % for all the nanoemulgel formulations at10 h was 32.39, 39.75 and 45.9% respectively. Nanoemulgel was non-irritant as demonstrated by skin irritation studies in animals. Conclusion: Itraconazole nanoemulgels were proved to be potential for effective topical delivery of drug with enhanced bioavailability.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 15(2024), 3 vom: 18. März, Seite 165-179 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patil, Archana S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
304NUG5GF4 |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2023-0062 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367729881 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367729881 | ||
| 003 | DE-627 | ||
| 005 | 20240311232156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2023-0062 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM367729881 | ||
| 035 | |a (NLM)38282577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patil, Archana S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Formulation and evaluation of itraconazole-loaded nanoemulgel for efficient topical delivery to treat fungal infections |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: The clinical application of conventional oral dosage form of itraconazole is limited due to its poor bioavailability. The aim of the study was to develop nanoemulgel of Itraconazole for topical delivery. Method: Nanoemulsions were prepared, optimized and further incorporated into a gel and evaluated for homogeneity, pH, viscosity, spreadability, in vitro drug release and skin irritation studies. Results: Cumulative drug release from nanoemulsions was within the range of 37.24 to 47.63% at 10 h. Drug release % for all the nanoemulgel formulations at10 h was 32.39, 39.75 and 45.9% respectively. Nanoemulgel was non-irritant as demonstrated by skin irritation studies in animals. Conclusion: Itraconazole nanoemulgels were proved to be potential for effective topical delivery of drug with enhanced bioavailability | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cutaneous fungal infection | |
| 650 | 4 | |a itraconazole | |
| 650 | 4 | |a nanoemulgel | |
| 650 | 4 | |a nanoemulsion | |
| 650 | 4 | |a topical delivery | |
| 650 | 7 | |a Itraconazole |2 NLM | |
| 650 | 7 | |a 304NUG5GF4 |2 NLM | |
| 650 | 7 | |a Emulsions |2 NLM | |
| 700 | 1 | |a Chougale, Samradni S |e verfasserin |4 aut | |
| 700 | 1 | |a Kokatanr, Umashri |e verfasserin |4 aut | |
| 700 | 1 | |a Hulyalkar, Sujay |e verfasserin |4 aut | |
| 700 | 1 | |a Hiremath, Ravindra D |e verfasserin |4 aut | |
| 700 | 1 | |a Japti, Veerkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Masareddy, Rajashree |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 15(2024), 3 vom: 18. März, Seite 165-179 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:3 |g day:18 |g month:03 |g pages:165-179 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2023-0062 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 3 |b 18 |c 03 |h 165-179 | ||